Ignite Creation Date:
2024-05-06 @ 3:26 AM
Last Modification Date:
2024-10-26 @ 11:34 AM
Study NCT ID:
NCT02299505
Status:
COMPLETED
Last Update Posted:
2022-02-09
First Post:
2014-11-14
Brief Title:
Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With ALK-positive Metastatic Non-small Cell Lung Cancer NSCLC
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-04-09
Start Date Type:
ACTUAL
Primary Completion Date:
2016-06-16
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-03-06
Completion Date Type:
ACTUAL
First Submit Date:
2014-11-14
First Submit QC Date:
November 20 2014
Study First Post Date:
2014-11-24
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-02-07
Last Update Post Date:
2022-02-09
Last Update Post Date Type:
ACTUAL